Publications

Publication of research results is a pivotal requirement for a comprehensive improvement of treatment concepts. iOMEDICO supports the international guidelines for transparency and reporting of medical research results.

We regularly present our data at national and international conferences. Our publications are published in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and scientists of iOMEDICO.

TITEL
STUDIE
JAHR
Nab-paclitaxel plus carboplatin as first-line therapy for patients with advanced NSCLC in the real-world setting: Safety results of the non-interventional NEPTUN study.

Dechow, T., Riera-Knorrenschild, J., Hackanson, B., Fischer von Weikersthal, L., Chiabudini, M., Timm, B., Zerbes, R.M., Potthoff, K., 2020.

Oncol Res Treat 43 (suppl 1)(276), 112.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
NEPTUN
2020
Real-world testing patterns for BRAF-mutations and treatment of patients with BRAF-mutated metastatic colorectal cancer: Results from the German Tumor Registry Colorectal Cancer (TKK Registry)

Zahn, M.-O., Dörfel, S, Schulz, H., Wolf, T., Vehling-Kaiser, U., Tech, S., Jänicke, M., Wetzel, N., Marschner N., 2020.

Oncol Res Treat 43(suppl 1)(426), 52.

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
TKK
2020
The Prospective Intersectoral National Cohort Study MYRIAM To Study Characteristics, Treatment And Outcome Of Patients With Multiple Myeloma In Germany.

Knauf, W., Engelhardt, M., Losem, C., Lipke, J., Kasper, C., Houet, L., Medinger, T., Jänicke, M., Marschner, N., Dechow, T., Einsele, H., 2020.

Oncol Res Treat, DKK 43 (suppl 1)(392), 130.

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DKK / Journal: Oncology Research and Treatment
MYRIAM
2020
Routine care of advanced breast cancer: the prospective, national research platform OPAL for patients with advanced breast cancer in Germany.

Decker T., Harbeck N., Thill M., Zahn M.-O., Nusch A., Lorenz A., Söling U., Chiabudini M., Kruggel L., Jänicke M., Marschner N., Stickeler E., Wöckel A., Welt A., 2020.

Oncol Res Treat 43(suppl 1)(254), 12.

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
OPAL
2020
Reduction of severity of chemotherapy-induced peripheral neuropathy by OnLife®14.02.2020 Final results of the breast cancer cohort of the STEFANO trial.

Zaiss, M., Uhlig, J., Zahn, M.-O., Decker, T., Lehmann, H., Harde, J., Hogrefe, C., Vannier, C., Marschner, N., 2020.

Oncol Res Treat 43 (suppl 1)(405), 185.

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
STEFANO
2020
Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study.

Lüftner, D., Welslau, M., Liersch, R., Deryal, M., Brucker, C., Rauh, J., Welt, A., Zaiss, M., Houet, L., Vannier, C., Potthoff, K., Marschner, N., 2020.

Oncol Res Treat 43 (suppl 1)(272), 14.

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
INGE-B
2020
Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study.

Welt, A., Welslau, M., Lüftner, D., Deryal, M., Liersch, R., Sahlmann, J., Houet, L., Potthoff, K., Marschner, N., 2020.

Oncol Res Treat 43 (suppl 1)(270), 13–14.

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
INGE-B
2020
Palbociclib in combination with anastrozole or exemestane for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany. Interim results of the INGE-B phase 2 trial.

M. Welslau, N. Marschner, U. Söling, C. Brucker, O.J. Stoetzer, J. Meiler, P.Wimberger, S.Dörfel, J.Sahlmann, L.Houet, C.Vannier, K.Potthoff, 2019.

Cancer Res February 15 2020 (80) (4 Supplement) P5-11-14

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: SABCS / Journal: Cancer Research
INGE-B
2019
Therapy of advanced breast cancer for patients with hormone receptor-positive / HER2-negative and HER2-positive tumors is changing real life. First results from the prospective, national research platform OPAL for patients with advanced breast cancer in Germany.

E. Stickeler, N. Harbeck, M. Thill, A. Nusch, M. Chiabudini, L. Kruggel, M. Jänicke, N. Marschner, M. Zahn, A. Welt, A. Wöckel, T. Decker, OPAL study group, 2019.

Cancer Res 80 (4 Suppl). https://doi.org/10.1158/1538-7445.SABCS19-P2-17-01

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: SABCS / Journal: Cancer Research
OPAL
2019
Negative impact of disease progression on quality of life of patients with advanced breast cancer – Data from the TMK/MaLife project.

Marschner N, Zacharias S, Welt A, Decker T, Nusch A, Kruggel L, Jänicke M, for the TMK Registry group, 2019.

The Breast 48 (suppl2), 71. https://doi.org/10.1016/S0960-9776(19)30610-1

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ABC5 / Journal: The Breast
TMK
2019